"Controversial FDA Decision: ALS Drug Relyvrio Fails Trial and Faces Market Withdrawal"
TL;DR Summary
The failure of the ALS drug Relyvrio, approved by the FDA based on a single clinical trial, has sparked debate over the agency's flexible approach to approving drugs for devastating conditions like ALS. Amylyx Pharmaceuticals, the drug's maker, is considering pulling it from the market after a larger trial showed it doesn't work, causing an 80% stock market value loss. Critics argue that FDA's leniency in approvals sets a risky precedent, while advocates emphasize the urgent need for effective treatments for ALS.
- The failure of ALS drug Relyvrio spotlights controversial FDA calls The Washington Post
- Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More Yahoo Finance
- Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry STAT
- Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. The Wall Street Journal
- A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market The New York Times
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
8 min
vs 9 min read
Condensed
95%
1,636 → 82 words
Want the full story? Read the original article
Read on The Washington Post